{
    "clinical_study": {
        "@rank": "385",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 10, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04269525"
        },
        "id_info": {
            "org_study_id": "2020002",
            "nct_id": "NCT04269525"
        },
        "brief_title": "Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia",
        "official_title": "Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection",
        "sponsors": {
            "lead_sponsor": {
                "agency": "ZhiYong Peng",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Tuohua Biological Technology Co. Ltd",
                "agency_class": "Other"
            }
        },
        "source": "Zhongnan Hospital",
        "oversight_info": {
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats\n      patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases.\n      And this study is conducted to find out whether or not it will function in 2019-nCOV\n      infection Pneumonia."
        },
        "detailed_description": {
            "textblock": "Serious Pneumonia and Critical Pneumonia caused by the 2019-nCOV infection greatly threats\n      patients' life, UC-MSCs treatment has been proved to play a role in curing multiple diseases.\n      And this study is conducted to find out whether or not it will function in 2019-nCOV\n      infection Pneumonia. And we are going to get the permission of the enrolled patients. Besides\n      the present clinical treatment, UC-MSCs treatment will be applied to those fulfilling the\n      enrollment. After a period of UC-MSCs treatment, the analysis of UC-MSCs treatment will be\n      completed from related aspects."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "February 6, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "April 30, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "intervention_model": "Single Group Assignment",
            "intervention_model_description": "reaching the criteria of pneumonia according to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4)",
            "primary_purpose": "Prevention",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Oxygenation index",
            "time_frame": "on the day 14 after enrollment",
            "description": "partial arterial oxygen pressure (PaO2) / oxygen concentration (FiO2)"
        },
        "secondary_outcome": [
            {
                "measure": "28 day mortality",
                "time_frame": "on the day 28 after enrollment",
                "description": "whether the patient survives"
            },
            {
                "measure": "Hospital stay",
                "time_frame": "up to 6 months",
                "description": "days of the patients in hospital"
            },
            {
                "measure": "2019-nCoV nucleic acid test",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "whether or not the 2019-nCoV nucleic acid test is positive"
            },
            {
                "measure": "Improvement of lung imaging examinations",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "whether lung imaging examinations show the improvement of the pneumonia"
            },
            {
                "measure": "White blood cell count",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "counts of white blood cell in a litre of blood"
            },
            {
                "measure": "Lymphocyte count",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "counts of lymphocyte in a litre (L) of blood"
            },
            {
                "measure": "Lymphocyte percentage",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "percentage of lymphocyte in white blood cell"
            },
            {
                "measure": "Procalcitonin",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "procalcitonin in microgram(ug)/L"
            },
            {
                "measure": "interleukin(IL)-2",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "IL-2 in picogram(pg)/millilitre(mL)"
            },
            {
                "measure": "IL-4",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "IL-4 in pg/mL"
            },
            {
                "measure": "IL-6",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "IL-6 in pg/mL"
            },
            {
                "measure": "IL-8",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "IL-8 in pg/mL"
            },
            {
                "measure": "IL-10",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "IL-10 in pg/mL"
            },
            {
                "measure": "tumor necrosis factor(TNF)-\u03b1",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "TNF-\u03b1 in nanogram(ng)/L"
            },
            {
                "measure": "\u03b3-interferon(IFN)",
                "time_frame": "on the day 7,14,28 after enrollment",
                "description": "\u03b3-IFN in a thousand unit (KU)/L"
            }
        ],
        "number_of_arms": "1",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "10"
        },
        "condition": [
            "Pneumonia, Viral",
            "Pneumonia, Ventilator-Associated"
        ],
        "arm_group": {
            "arm_group_label": "pneumonia",
            "arm_group_type": "Experimental",
            "description": "According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored."
        },
        "intervention": {
            "intervention_type": "Biological",
            "intervention_name": "UC-MSCs",
            "description": "After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.",
            "arm_group_label": "pneumonia"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-75 years old ,no gender restriction\n\n          -  According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV\n             infection(Trial Version 4), patients are diagnosed with severe or critical 2019-nCoV\n             pneumonia with stay in the ICU of less than 48 hours\n\n          -  Women of childbearing age should have a negative blood pregnancy test before the start\n             of dosing and agree to take effective contraceptive measures during the trial until\n             the last follow-up (28 days)\n\n          -  Sequential Organ Failure Assessment(SOFA) score between 2-13 point\n\n          -  Voluntarily participate in this clinical study and sign a written informed consent. If\n             the patient cannot obtain informed consent, he can authorize his legal representative.\n\n        Exclusion Criteria:\n\n          -  Liver or kidney SOFA score of more than 3 points;\n\n          -  HIV positive\n\n          -  Highly allergic constitution or history of severe allergies;\n\n          -  Pregnant and lactating women;\n\n          -  Patients with malignant tumors;\n\n          -  Patients with previous history of pulmonary embolism;\n\n          -  Participating in clinical trials of other drugs within 3 months before enrollment.\n\n          -  be thought by researchers to be inappropriate to participate in this clinical study."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "75 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "XingHuan Wang, professor",
            "role": "Study Chair",
            "affiliation": "Wuhan University"
        },
        "overall_contact": {
            "last_name": "XingHuan Wang, professor",
            "phone": "18971387168",
            "email": "znyylcsy@126.com"
        },
        "overall_contact_backup": {
            "last_name": "ZhiYong Peng, professor",
            "phone": "18672396028",
            "email": "pengzy5@hotmail.com"
        },
        "location": {
            "facility": {
                "name": "Zhongnan Hospital of Wuhan University",
                "address": {
                    "city": "Wuhan",
                    "state": "Hubei",
                    "zip": "430000",
                    "country": "China"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "XingHuan Wang, professor"
            },
            "contact_backup": {
                "last_name": "ZhiYong Peng, professor"
            },
            "investigator": [
                {
                    "last_name": "XingHuan Wang",
                    "role": "Principal Investigator"
                },
                {
                    "last_name": "ZhiYong Peng",
                    "role": "Principal Investigator"
                }
            ]
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "February 2020",
        "study_first_submitted": "February 7, 2020",
        "study_first_submitted_qc": "February 12, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "February 13, 2020"
        },
        "last_update_submitted": "February 12, 2020",
        "last_update_submitted_qc": "February 12, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "February 17, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor-Investigator",
            "investigator_affiliation": "Zhongnan Hospital",
            "investigator_full_name": "ZhiYong Peng",
            "investigator_title": "professor"
        },
        "keyword": [
            "2019-nCOV infection",
            "UC-MSCs Treatment"
        ],
        "condition_browse": {
            "mesh_term": [
                "Pneumonia, Ventilator-Associated",
                "Pneumonia, Viral",
                "Pneumonia"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}